Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Deffered Revenue (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 47.18% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 47.18% year-over-year, with the annual reading at $1.8 million for FY2025, 47.18% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $1.8 million at Caribou Biosciences, roughly flat from $1.8 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $24.2 million in Q2 2021, with the low at $1.8 million in Q4 2025.
  • Average Non-Current Deffered Revenue over 5 years is $9.3 million, with a median of $5.8 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue surged 660.8% in 2022, then crashed 74.65% in 2024.
  • Over 5 years, Non-Current Deffered Revenue stood at $2.1 million in 2021, then soared by 660.8% to $16.0 million in 2022, then tumbled by 61.75% to $6.1 million in 2023, then tumbled by 45.64% to $3.3 million in 2024, then plummeted by 47.18% to $1.8 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $1.8 million, $1.8 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.